Diaphragm Function After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

June 7, 2024

Study Completion Date

June 8, 2024

Conditions
Neuromuscular Block, Residual
Interventions
DRUG

Sugammadex

"* Sugammadex(100mg/mL), 2mg/kg~* After confirming Train-of-four counts 4, patients allocated to sugammadex group receive sugammadex 2mg/kg for reversal of rocuronium at the end of the surgery."

DRUG

Neostigmine

"* Neostigmine methylsulfate(0.5mg/mL) 0.02mg/kg~* After confirming Train-of-four counts 4, patients allocated to neostigmine group receive neostigmine 0.02mg/kg (maximum 5mg) combined with atropine 0.02mg/kg for reversal of rocuronium at the end of the surgery."

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER